Evidence map›Paper›PMID 36707887›Full record

ArticleAlzheimer's research & therapy2023

Altered dynamics of glymphatic flow in a mature-onset Tet-off APP mouse model of amyloidosis.

Inès R H Ben-Nejma, Aneta J Keliris, Verdi Vanreusel, Peter Ponsaerts, Annemie Van der Linden, Georgios A Keliris

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Alzheimer's disease pathophysiology in the Retina.Progress in retinal and eye research · 2024
    Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Inès R H Ben-Nejma *Bio-Imaging Lab, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Antwerp, Belgium. InesRHBenNejma@icloud.com.
Aneta J Keliris *Bio-Imaging Lab, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Antwerp, Belgium. aneta.keliris@outlook.com.
Verdi VanreuselBio-Imaging Lab, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Antwerp, Belgium.
Peter PonsaertsLaboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Antwerp, Belgium.
Annemie Van der LindenBio-Imaging Lab, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Antwerp, Belgium.
Georgios A KelirisBio-Imaging Lab, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Antwerp, Belgium. georgios.keliris@outlook.com.
University of Antwerp · BEBelgian Nuclear Research Centre · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is an incurable neurodegenerative disorder characterised by the progressive buildup of toxic amyloid-beta (Aβ) and tau protein aggregates eventually leading to cognitive decline. Recent lines of evidence suggest that an impairment of the glymphatic system (GS), a brain waste clearance pathway, plays a key role in the pathology of AD. Moreover, a relationship between GS function and neuronal network integrity has been strongly implicated. Here, we sought to assess the efficacy of the GS in a transgenic Tet-Off APP mouse model of amyloidosis, in which the expression of mutant APP was delayed until maturity, mimicking features of late-onset AD-the most common form of dementia in humans.

methodsTo evaluate GS function, we used dynamic contrast-enhanced MRI (DCE-MRI) in 14-month-old Tet-Off APP (AD) mice and aged-matched littermate controls. Brain-wide transport of the Gd-DOTA contrast agent was monitored over time after cisterna magna injection. Region-of-interest analysis and computational modelling were used to assess GS dynamics while characterisation of brain tissue abnormalities at the microscale was performed ex vivo by immunohistochemistry.

resultsWe observed reduced rostral glymphatic flow and higher accumulation of the contrast agent in areas proximal to the injection side in the AD group. Clustering and subsequent computational modelling of voxel time courses revealed significantly lower influx time constants in AD relative to the controls. Ex vivo evaluation showed abundant amyloid plaque burden in the AD group coinciding with extensive astrogliosis and microgliosis. The neuroinflammatory responses were also found in plaque-devoid regions, potentially impacting brain-fluid circulation.

conclusionsIn a context resembling late-onset AD in humans, we demonstrate the disruption of glymphatic function and particularly a reduction in brain-fluid influx in the AD group. We conjecture that the hindered circulation of cerebrospinal fluid is potentially caused by wide-spread astrogliosis and amyloid-related obstruction of the normal routes of glymphatic flow resulting in redirection towards caudal regions. In sum, our study highlights the translational potential of alternative approaches, such as targeting brain-fluid circulation as potential therapeutic strategies for AD.

Indexed as

Alzheimer DiseaseAmyloidosisAgedAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBrainContrast MediaDisease Models, AnimalGliosisHumansInfantMiceMice, TransgenicPlaque, AmyloidAmyloid beta-PeptidesAmyloid beta-Protein PrecursorContrast MediaAmyloid-betaAstrogliosisBrain-fluid circulationDCE-MRIForebrain amyloidosisGlymphatic systemInflammationMature-onset Tet-off mice

Identifiers

PMID36707887
PMCPMC9883946
OpenAlexW4318318157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.